|
1
|
Stupp R, Mason WP, van den Bent MJ, et al:
Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
DeAngelis LM: Brain tumors. N Engl J Med.
344:114–123. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Laws ER, Parney IF, Huang W, et al:
Survival following surgery and prognostic factors for recently
diagnosed malignant glioma: data from the Glioma Outcomes Project.
J Neurosurg. 99:467–473. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kapoor R, Revesz T and Powell M: Solitary
cervical lymphoma presenting as a neurofibroma. Br J Neurosurg.
6:583–586. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Perry JR, Bélanger K, Mason WP, et al:
Phase II trial of continuous dose-intense temozolomide in recurrent
malignant glioma: RESCUE study. J Clin Oncol. 28:2051–2057. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mirimanoff RO, Gorlia T, Mason W, et al:
Radiotherapy and temozolomide for newly diagnosed glioblastoma:
recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3
phase III randomized trial. J Clin Oncol. 24:2563–2569. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mrugala MM and Chamberlain MC: Mechanisms
of disease: temozolomide and glioblastoma - look to the future. Nat
Clin Pract Oncol. 5:476–486. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kohsaka S, Wang L, Yachi K, et al: STAT3
inhibition overcomes temozolomide resistance in glioblastoma by
downregulating MGMT expression. Mol Cancer Ther. 11:1289–1299.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kohsaka S, Takahashi K, Wang L, et al:
Inhibition of GSH synthesis potentiates temozolomide-induced
bystander effect in glioblastoma. Cancer Lett. 331:68–75. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Joe B, Vijaykumar M and Lokesh BR:
Biological properties of curcumin-cellular and molecular mechanisms
of action. Crit Rev Food Sci Nutr. 44:97–111. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Maheshwari RK, Singh AK, Gaddipati J and
Srimal RC: Multiple biological activities of curcumin: a short
review. Life Sci. 78:2081–2087. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kunnumakkara AB, Anand P and Aggarwal BB:
Curcumin inhibits proliferation, invasion, angiogenesis and
metastasis of different cancers through interaction with multiple
cell signaling proteins. Cancer Lett. 269:199–225. 2008. View Article : Google Scholar
|
|
13
|
Das T, Sa G, Saha B and Das K: Multifocal
signal modulation therapy of cancer: ancient weapon, modern
targets. Mol Cell Biochem. 336:85–95. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Basile V, Ferrari E, Lazzari S, Belluti S,
Pignedoli F and Imbriano C: Curcumin derivatives: molecular basis
of their anticancer activity. Biochem Pharmacol. 78:1305–1315.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hussain AR, Al-Rasheed M, Manogaran PS, et
al: Curcumin induces apoptosis via inhibition of PI3′-kinase/AKT
pathway in acute T cell leukemias. Apoptosis. 11:245–254.
2006.PubMed/NCBI
|
|
16
|
Zheng S and Chen A: Activation of
PPARgamma is required for curcumin to induce apoptosis and to
inhibit the expression of extracellular matrix genes in hepatic
stellate cells in vitro. Biochem J. 384:149–157. 2004. View Article : Google Scholar
|
|
17
|
Lu JJ, Cai YJ and Ding J: The short-time
treatment with curcumin sufficiently decreases cell viability,
induces apoptosis and copper enhances these effects in
multidrug-resistant K562/A02 cells. Mol Cell Biochem. 360:253–260.
2012. View Article : Google Scholar
|
|
18
|
Ramachandran C, Nair SM, Escalon E and
Melnick SJ: Potentiation of etoposide and temozolomide cytotoxicity
by curcumin and turmeric force in brain tumor cell lines. J
Complement Integr Med. 9:Article 20. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen CC, Taniguchi T and D’Andrea A: The
Fanconi anemia (FA) pathway confers glioma resistance to DNA
alkylating agents. J Mol Med. 85:497–509. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Roos WP, Batista LF, Naumann SC, et al:
Apoptosis in malignant glioma cells triggered by the
temozolomide-induced DNA lesion O6-methylguanine.
Oncogene. 26:186–197. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lin CJ, Lee CC, Shih YL, et al:
Resveratrol enhances the therapeutic effect of temozolomide against
malignant glioma in vitro and in vivo by inhibiting autophagy. Free
Radic Biol Med. 52:377–391. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sánchez Y, Simón GP, Calviño E, de Blas E
and Aller P: Curcumin stimulates reactive oxygen species production
and potentiates apoptosis induction by the antitumor drugs arsenic
trioxide and lonidamine in human myeloid leukemia cell lines. J
Pharmacol Exp Ther. 335:114–123. 2010.
|
|
23
|
Hirose Y, Katayama M, Mirzoeva OK, Berger
MS and Pieper RO: Akt activation suppresses Chk2-mediated,
methylating agent-induced G2 arrest and protects from
temozolomide-induced mitotic catastrophe and cellular senescence.
Cancer Res. 65:4861–4869. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen L, Han L, Shi Z, et al: LY294002
enhances cytotoxicity of temozolomide in glioma by down-regulation
of the PI3K/Akt pathway. Mol Med Rep. 5:575–579. 2012.PubMed/NCBI
|
|
25
|
Yu S, Shen G, Khor TO, Kim JH and Kong AN:
Curcumin inhibits Akt/mammalian target of rapamycin signaling
through protein phosphatase-dependent mechanism. Mol Cancer Ther.
7:2609–2620. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Datta SR, Dudek H, Tao X, et al: Akt
phosphorylation of BAD couples survival signals to the
cell-intrinsic death machinery. Cell. 91:231–241. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang J, Stevens MF and Bradshaw TD:
Temozolomide: mechanisms of action, repair and resistance. Curr Mol
Pharmacol. 5:102–114. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gupta SC, Patchva S, Koh W and Aggarwal
BB: Discovery of curcumin, a component of golden spice, and its
miraculous biological activities. Clin Exp Pharmacol Physiol.
39:283–299. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hegi ME, Diserens AC, Gorlia T, et al:
MGMT gene silencing and benefit from temozolomide in
glioblastoma. N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar
|
